H+H International A/S
CEO Michael T Andersen receives shares in H+H International A/S under matching share program from 2018
H+H International A/S has received notification pursuant to article 19 of EU Regulation no. 596/2014 of the below transaction(s) related to shares or other financial instruments in H+H International A/S made by persons discharging managerial responsibilities in H+H International A/S or persons closely related to them.
1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Michael Troensegaard Andersen
2. Reason for the notification
a) Position/status: CEO
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: H+H International A/S
b) LEI: LEI: 3800GJODT6FV8QM841
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument:
- Type of instrument: Shares
- Identification code: DK0015202451
b) Nature of the transaction: Vesting of H+H shares under matching share program initiated in 2018. The shares are granted by H+H International A/S.
c) Price(s) and volume(s):
| Price(s) | Volume(s) |
| DKK 0 per pcs. | 6,851 |
d) Aggregated information
- Aggregated volume: N/A
- Aggregated price: N/A
e) Date of the transaction(s): 2021-03-04
f) Place of the transaction: N/A
For further information please contact:
Andreas Holkjær
Investor Relations and Treasury Manager
+45 24 48 03 67
aho@HplusH.com
H+H International A/S’s core activity is the manufacture and sale of wall building materials, with a revenue in 2020 of DKK 2,654 million. The main product lines are aircrete blocks and calcium silicate units used for the residential new building segment. H+H has 29 factories in Northern and Central Europe with a total output of more than 4 million cubic metres of products annually and has a leading position in most of its markets. H+H has more than 1,500 employees and is listed on Nasdaq Copenhagen.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S3.11.2025 15:05:00 CET | Press release
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Infoblox Inc.3.11.2025 15:00:00 CET | Press release
Infoblox Surpasses 200 Customers in Breakout Year for Universal DDI™ and Announces New Capabilities for Network Transformation
Evaxion3.11.2025 15:00:00 CET | Press release
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
F. Hoffmann-La Roche Ltd3.11.2025 15:00:00 CET | Press release
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
AIM ImmunoTech Inc.3.11.2025 14:55:00 CET | Press release
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
